{"title":"Shaping the Future of Prostate Cancer Care: The Promise and Pitfalls of Gene- and Cell-Based Therapeutics.","authors":"Dherya Guleria, Navjot Kaur Sandhu","doi":"10.2174/0115665232479483260416092641","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate Cancer (PCa) affects the population worldwide on a large scale in men. This paper presents a comprehensive overview of the evolving therapeutic landscape for PCa and highlights the promise and challenges of gene- and cell-based strategies. There are various limitations to conventional modalities, such as radiotherapy, chemotherapy, and surgery; however, the growing impact of molecular precision, immunotherapies, and innovative gene-editing tools, such as the clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) system, minimizes the limitations of these conventional therapies. Comparisons of the current progress in Oncolytic Virus (OV) based therapies, viral and non-viral gene delivery systems, and cell-based immunotherapies including Chimeric Antigen Receptor (CAR) T cells and Dendritic Cell (DC) therapies demonstrate both their therapeutic potentials and key challenges to their effectiveness that include Tumor Heterogeneity (TH), immune evasion, and the immunosuppressive Tumor Microenvironment (TME). The combination approach integrates the control point blockade, radiosensitizing chemotherapeutics, and biomarker-guided interventions to improve treatment outcomes. It also provides a perspective for analyzing the future roles of Artificial Intelligence (AI), multi-omics integration, and collaborative research networks in shaping standards that are more personalized to enhance care for PCa patients.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232479483260416092641","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate Cancer (PCa) affects the population worldwide on a large scale in men. This paper presents a comprehensive overview of the evolving therapeutic landscape for PCa and highlights the promise and challenges of gene- and cell-based strategies. There are various limitations to conventional modalities, such as radiotherapy, chemotherapy, and surgery; however, the growing impact of molecular precision, immunotherapies, and innovative gene-editing tools, such as the clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) system, minimizes the limitations of these conventional therapies. Comparisons of the current progress in Oncolytic Virus (OV) based therapies, viral and non-viral gene delivery systems, and cell-based immunotherapies including Chimeric Antigen Receptor (CAR) T cells and Dendritic Cell (DC) therapies demonstrate both their therapeutic potentials and key challenges to their effectiveness that include Tumor Heterogeneity (TH), immune evasion, and the immunosuppressive Tumor Microenvironment (TME). The combination approach integrates the control point blockade, radiosensitizing chemotherapeutics, and biomarker-guided interventions to improve treatment outcomes. It also provides a perspective for analyzing the future roles of Artificial Intelligence (AI), multi-omics integration, and collaborative research networks in shaping standards that are more personalized to enhance care for PCa patients.
期刊介绍：
Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases.
Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
